Autolus Therapeutics annual debt-to-equity ratio
2017
2018
2019
2020
2021
2022
2023
2024
2025
Autolus Therapeutics Debt-to-Equity Ratio Growth & History (AUTL)
Autolus Therapeutics's debt-to-equity ratio was 0.40 for fiscal 2025.
View full Autolus Therapeutics company overviewAutolus Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.40 | 0.28 | +225.40% |
| 2024 | 2024-12-31 | 0.12 | −0.35 | −74.08% |
| 2023 | 2023-12-31 | 0.48 | 0.39 | +485.07% |
| 2022 | 2022-12-31 | 0.08 | 0.01 | +21.18% |
| 2021 | 2021-12-31 | 0.07 | −0.19 | −74.01% |
| 2020 | 2020-12-31 | 0.26 | 0.15 | +150.62% |
| 2019 | 2019-12-31 | 0.10 | — | — |
| 2018 | 2018-09-30 | 0.00 | −0.00 | −72.20% |
| 2017 · Sep 30 | 2017-09-30 | 0.01 | — | — |
Autolus Therapeutics quarterly debt-to-equity ratio
Q4.18
Q1.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q4.21
Q4.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 1.12 | 0.93 | +499.08% |
| Q1 2026 | 2026-03-31 | 0.73 | 0.58 | +372.48% |
| Q4 2025 | 2025-12-31 | 0.40 | 0.28 | +225.40% |
| Q3 2025 | 2025-09-30 | 0.25 | 0.14 | +126.49% |
| Q2 2025 | 2025-06-30 | 0.19 | 0.09 | +96.56% |
| Q1 2025 | 2025-03-31 | 0.16 | 0.07 | +76.30% |
| Q4 2024 | 2024-12-31 | 0.12 | −0.35 | −74.08% |
| Q3 2024 | 2024-09-30 | 0.11 | −0.18 | −62.32% |
| Q2 2024 | 2024-06-30 | 0.09 | — | — |
| Q1 2024 | 2024-03-31 | 0.09 | — | — |
| Q4 2023 | 2023-12-31 | 0.48 | 0.39 | +485.07% |
| Q3 2023 | 2023-09-30 | 0.29 | — | — |
| Q4 2022 | 2022-12-31 | 0.08 | 0.01 | +21.18% |
| Q4 2021 | 2021-12-31 | 0.07 | −0.19 | −74.01% |
| Q1 2021 | 2021-03-31 | 0.08 | −0.02 | −16.35% |
| Q4 2020 | 2020-12-31 | 0.26 | 0.15 | +150.62% |
| Q3 2020 | 2020-09-30 | 0.22 | 0.12 | +125.30% |
| Q2 2020 | 2020-06-30 | 0.11 | 0.02 | +17.98% |
| Q1 2020 | 2020-03-31 | 0.09 | — | — |
| Q4 2019 | 2019-12-31 | 0.10 | 0.10 | +8298.98% |
| Q3 2019 · Sep 30 | 2019-09-30 | 0.10 | 0.10 | +6561.65% |
| Q3 2019 · Jun 30 | 2019-06-30 | 0.09 | — | — |
| Q1 2019 | 2018-12-31 | 0.00 | — | — |
| Q4 2018 | 2018-09-30 | 0.00 | — | — |
Autolus Therapeutics debt-to-equity ratio trends
Over the last five fiscal years, Autolus Therapeutics's debt-to-equity ratio increased from 0.26 to 0.40, a change of 0.14. The latest reported quarter, Q2 2026, shows 1.12.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Autolus Therapeutics source filings ↗